Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 2,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of a Novel Probiotic on Gastrointestinal Health in Generally Healthy Adults

NCT05595980
View directory record Official record
Conditions
Gastrointestinal Health, Immune Health, Digestive Health
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
BIO-CAT Microbials, LLC
Industry
Eligibility
30 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Nov 4, 2026, 4:38 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

An RCT Evaluating the Efficacy of a Skincare Routine and Acne Supplement on Improving Acne and Other Symptoms of PMS

NCT06018168
View directory record Official record
Conditions
Acne, Premenstrual Syndrome
Interventions
Skincare Routine, MINDBODYSKIN Supplement
Other · Dietary Supplement
Lead sponsor
Clearstem Skincare
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Nov 4, 2026, 4:38 AM EST
Completed Phase 4 Interventional Results available

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

NCT04792190
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
dapagliflozin, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Portland, Maine • Detroit, Michigan • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Nov 4, 2026, 4:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Effects of CBD Products on Anxiety Among U.S. Women

NCT05108220
View directory record Official record
Conditions
Anxiety, Generalized Anxiety Disorder
Interventions
Cannabidiol (CBD)- containing consumer products
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
24 Years to 44 Years · Female only
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 4, 2026, 4:38 AM EST
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD

NCT03950882
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
PXL770, Placebo
Drug
Lead sponsor
Poxel SA
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Nov 4, 2026, 4:38 AM EST
Completed Phase 3 Interventional Results available

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

NCT01120691
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QVA149, NVA237, tiotropium, Salbutamol/albuterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
2,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
53
States / cities
Birmingham, Alabama • Fairhope, Alabama • Florence, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Nov 4, 2026, 4:38 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

NCT04663308
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
34
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 4, 2026, 4:38 AM EST
Completed Phase 4 Interventional Results available

A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD

NCT01749215
View directory record Official record
Conditions
Alcohol Dependence, Posttraumatic Stress Disorder (PTSD)
Interventions
Topiramate, placebo, Medical Management
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Nov 4, 2026, 4:38 AM EST
Recruiting Early Phase 1 Interventional

Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder

NCT06934915
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder, Autism
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Christopher John McDougle, M.D.
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 4, 2026, 4:38 AM EST
Recruiting Phase 4 Interventional

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

NCT04781140
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
100mg SPN-812, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
48 Months to 69 Months
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
54
States / cities
Saraland, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 4, 2026, 4:38 AM EST
Completed Phase 2 Interventional

Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy

NCT00481013
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Valproic Acid (VPA), Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Nov 4, 2026, 4:38 AM EST
Recruiting Phase 2 Interventional Accepts healthy volunteers

Postpartum Low-Dose Aspirin and Preeclampsia

NCT03667326
View directory record Official record
Conditions
Preeclampsia Postpartum
Interventions
Aspirin tablet, Placebo oral capsule
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Nov 4, 2026, 4:38 AM EST
Recruiting Phase 2 Interventional

Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD

NCT04984226
View directory record Official record
Conditions
Chronic Kidney Diseases, Metabolic Acidosis, Fatigue, Physical Endurance, Insulin Resistance, Mitochondrial Energetics, Diabetes
Interventions
Sodium bicarbonate, placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Sacramento, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 4, 2026, 4:38 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of TA-65MD on Healthy Volunteers

NCT02766790
View directory record Official record
Conditions
Healthy
Interventions
TA-65MD, Placebo
Dietary Supplement · Other
Lead sponsor
Telomerase Activation Sciences, Inc
Industry
Eligibility
45 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Springfeild, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Nov 4, 2026, 4:38 AM EST
Completed Phase 3 Interventional Results available

Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy

NCT01500226
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, Dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Nov 4, 2026, 4:38 AM EST
Enrolling by invitation Phase 2 Interventional

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT05285878
View directory record Official record
Conditions
Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Nov 4, 2026, 4:38 AM EST
Completed Phase 2 Interventional Results available

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

NCT04002674
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Placebo oral capsule, Nilotinib Oral Capsule
Drug
Lead sponsor
Georgetown University
Other
Eligibility
25 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 4, 2026, 4:38 AM EST
Completed Phase 3 Interventional Results available

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

NCT00056160
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-5013, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
44
States / cities
Hoover, Alabama • Duarte, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Nov 4, 2026, 4:38 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation

NCT02647723
View directory record Official record
Conditions
Pregnancy, Child Development
Interventions
DHA, Sugar pill
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 4, 2026, 4:38 AM EST
Completed Phase 4 Interventional Results available

Evaluation Exparel Delivered in Knee Replacement

NCT02011464
View directory record Official record
Conditions
Arthritis
Interventions
Exparel, Saline
Drug · Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Nov 4, 2026, 4:38 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

NCT04313634
View directory record Official record
Conditions
Healthy
Interventions
Dasatinib, Quercetin, Fisetin
Drug
Lead sponsor
Sundeep Khosla, M.D.
Other
Eligibility
60 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Nov 4, 2026, 4:38 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

NCT03554304
View directory record Official record
Conditions
QT/QTc Interval in Healthy Volunteers
Interventions
WCK 5222, IV placebo matched to WCK 5222 / Moxifloxacin IV solution, Moxifloxacin 400-mg
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Nov 4, 2026, 4:38 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use

NCT07218549
View directory record Official record
Conditions
Opioid Use, Substance Use Disorders, Opioid Analgesia
Interventions
Placebo, Oxycodone HCl, Kratom 8g, Kratom 12g, Kratom 16g, Kratom 4g
Drug
Lead sponsor
Christopher D. Verrico
Other
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 4, 2026, 4:38 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Vicia Faba Hydrolysate Supplementation on Muscle Strength Recovery

NCT06837298
View directory record Official record
Conditions
Muscle Damage, Muscle
Interventions
Placebo control capsules, PeptiStrong® supplement capsules with same appearance as placebo capsules, PeptiStrong® supplement capsules following muscle damaging exercise on Day 14
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 45 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Nov 4, 2026, 4:38 AM EST